October 202633
SULT1A1 biomarkers for minoxidil may predict responders and enable personalized dosing. Topical finasteride in postmenopausal women improved hair density and thickness. Sodium citrate in growth-factor injections cut pain and improved density versus alternatives. Finasteride tapering after sexual side effects reportedly let men continue treatment, per its retrospective title. GLP-1 agonists and hair loss appear mostly transient telogen effluvium from rapid weight loss rather than drug toxicity, though paradoxical improvements are also reported. Laser-assisted growth-factor delivery raised density roughly 23–26% versus 5% with laser alone. PRP versus growth factor concentrate both helped, with evidence too heterogeneous to rank. Upadacitinib in adolescent alopecia areata ranked above baricitinib and ritlecitinib.
- “Personalized Minoxidil Therapy in Androgenetic Alopecia: From SULT1A1 Biomarkers to Precision Clinical Management” A review explains how follicular SULT1A1 enzyme activity may predict who responds to minoxidil and enable personalized treatment.
- Topical Finasteride 0.25% Solution for Female Pattern Hair Loss (FPHL) in Postmenopausal Women: A 52‐Week Retrospective Observational Study In 26 postmenopausal women, topical finasteride 0.25% monotherapy for 52 weeks improved hair density and thickness with no adverse events recorded.
- Optimizing Concentrated Growth Factor Therapy: Sodium Citrate Reduces Pain in Hair Loss Treatment In a 267-patient trial, sodium citrate as anticoagulant for concentrated growth factor injections cut pain and improved hair density versus alternatives.
- GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox? A review finds GLP-1-related hair loss is mostly transient telogen effluvium driven by rapid weight loss rather than drug toxicity, though paradoxical alopecia improvements are also reported.
- Finasteride tapering allows continuation of therapy in men with male pattern hair loss who develop sexual side effects: A retrospective study a retrospective study reports finasteride tapering let men with sexual side effects continue treatment for male pattern hair loss.
- Thulium laser-assisted delivery of growth factors for treating androgenetic alopecia – a randomized, controlled, clinical study In a pilot randomized study, laser-assisted growth-factor serum delivery improved hair density about 23–26% versus 5% with laser and light alone.
- Persistent chemotherapy-induced alopecia: a scoping review A scoping review of persistent chemotherapy-induced alopecia found scalp cooling preventive and low-dose oral minoxidil beneficial in all seven studies.
- Targeting fibroimmune remodeling in androgenetic alopecia: emerging opportunities for RNA-based drug discovery A review maps fibroimmune remodeling in androgenetic alopecia as a source of RNA-drug targets, still requiring human spatial validation.
- Comparative Efficacy of Ritlecitinib, Baricitinib, and Upadacitinib in Adolescents With Severe Alopecia Areata: A Bayesian Network Meta‑Analysis A Bayesian network meta-analysis found upadacitinib 30 mg most effective for adolescent severe alopecia areata, above baricitinib and ritlecitinib.
- Minoxidil and Prostaglandin Analogs for Chemotherapy-Induced Alopecia: A Scoping Review A scoping review found minoxidil aids regrowth but not prevention of chemotherapy-induced alopecia; prostaglandin analogs remain untested in this setting.
- Ritlecitinib: A Review in Severe Alopecia Areata A review finds ritlecitinib effective and generally well tolerated for severe alopecia areata, with responses sustained up to three years.
- A Novel Squid Ink–Quinolin Derived Compound (AEBI), Promotes Hair Growth and Enhances Hair Follicle Stem Cell Activity A novel squid-ink-derived compound stimulated hair follicle stem cells and regrew hair in depilated rats, rivaling 5% minoxidil.
- Real-World Safety of Janus Kinase Inhibitors in Alopecia Areata: A Propensity Score-Matched Cohort Study of a Global Federated Health Network In a matched real-world alopecia areata cohort, JAK inhibitors raised acne risk but not severe infections; a skin-cancer signal was not robust across analyses.
- Efficacy of platelet-rich plasma versus growth factor concentrate in androgenetic alopecia: a systematic review A systematic review found PRP and growth factor concentrate both improve hair outcomes in AGA, but evidence is too heterogeneous to declare a winner.
- Baricitinib Efficacy Through 4 Years in Responders and Safety up to 5 Years in Adults with Severe Alopecia Areata: Final Results from BRAVE-AA1 and BRAVE-AA2 In final BRAVE trial results, about 85% of baricitinib responders kept hair regrowth over four years, with serious-event rates remaining low and stable over five years.
- Exploratory Identification of Multidimensional Treatment-Response Profiles in Androgenetic Alopecia Treated with Combined Scalp Microneedling and Topical Minoxidil Using Unsupervised Clustering In 156 AGA patients on microneedling plus minoxidil, clustering suggested three response profiles, but baseline features could not predict them.
- Baricitinib response pattern by baseline nail involvement in children under 12 with alopecia areata A figure-based report tracks cumulative baricitinib response over 36 weeks by baseline nail involvement in children under 12 with alopecia areata.
- In Vivo Study of Topical Bimatoprost, Latanoprost, Travoprost in Comparison with Minoxidil on Hair Growth in C57BL/6 Mice In mice, topical bimatoprost and latanoprost increased hair density and follicle diameter more than 5% minoxidil over 28 days.
- Biologics in alopecia areata: promise, paradox, and the precision medicine frontier A review concludes cytokine-targeting biologics cannot be recommended for alopecia areata outside trials, given weak efficacy and paradoxical cases.
- Investigation of Clinical and Immunological Features of Alopecia Areata With Comorbid Atopic Dermatitis A 123-patient study characterizes alopecia areata with comorbid atopic dermatitis as a distinct Th2/ILC2-driven endotype.
- Ageratum conyzoides Extract Promotes Hair Shaft Thickness Accompanied by Increased Growth Factor Levels and Enhanced Antioxidant Status in C57BL/6 Mice In mice, oral Ageratum conyzoides extract sped hair regrowth, thickened shafts, and raised IGF-1, VEGF, and antioxidant markers.
- Transdermal L-arginine and hyaluronic acid delivery to treat androgenetic alopecia through dual hormone modulation and anti-inflammatory action In an AGA mouse model, liposomal transdermal L-arginine reduced DHT and inflammation while promoting hair regeneration.
- Platycladus orientalis Leaf-Derived Exosome-like Nanovesicles Delivered by Hydrogel Microneedles Restore Follicular Immune Homeostasis and Promote Hair Regeneration in Androgenetic Alopecia In an AGA mouse model, microneedles delivering plant-derived exosome-like vesicles restored follicular immune balance and regrew hair.
- Encapsulation-integrated microneedle platforms for alopecia treatment: a review of controlled drug delivery, immunomodulation, and hair follicle regeneration A review covers encapsulation-integrated microneedle platforms for controlled drug delivery and immune modulation in alopecia.
- The implications of biotin supplementation on multiple sclerosis, hair loss conditions, and thyroid disorders A review warns biotin supplements, even over-the-counter doses, can distort thyroid tests; stopping 24–72 hours often suffices for standard doses.
- Protective Effects of Phenytoin and Spironolactone against 5-Fluorouracil-induced Alopecia: Involvement of Antioxidant, Anti-inflammatory, and Collagen-regenerative Mechanisms In rats, oral phenytoin and spironolactone reduced 5-fluorouracil-induced alopecia via antioxidant and anti-inflammatory effects.
- Microneedle-based technology for treating hair loss disorders – an emerging trend for managing alopecia A review describes microneedle technology as an emerging painless drug-delivery approach for hair loss treatment.
- Microneedling with topical platelet-rich plasma versus triamcinolone acetonide for the treatment of alopecia areata in children: a comparative study In 30 children with alopecia areata, microneedling with topical triamcinolone beat PRP for short-term SALT improvement.
- Monitoring the Response to JAK Inhibitor Treatment in Alopecia Areata Using Reflectance Confocal Microscopy and Videotrichoscopy: A 60-Week Observational Study In 20 severe alopecia areata patients, confocal microscopy and trichoscopy tracked JAK inhibitor response and detected residual inflammation despite regrowth.
- Fractional Lasers for Hair Restoration: A Scoping Review A scoping review found fractional lasers show promise for hair restoration, but evidence comes from small studies.
- Shedding: An updated guide to a common cause of hair loss A clinical review guides diagnosis and management of telogen effluvium, focusing on trigger identification and reassurance.
- Patterns of Clinical Response in Rollover Adolescent Patients with Alopecia Areata Treated with Ritlecitinib in the Ongoing Long-Term, Open-Label, Phase 3 ALLEGRO-LT Study In adolescents on long-term ritlecitinib, 42% reached SALT ≤20 by 24 months; responders had shorter disease duration and less extensive loss.
- Hair follicle regeneration technology: from microenvironment regulation to functional reconstruction A review surveys hair follicle regeneration technologies from microenvironment modulation to engineered follicle organoids.